Multiple sclerosis

Additional courses of alemtuzumab effective and safe in RRMS

Up to two extra alemtuzumab courses may help mitigate clinical and MRI disease activity in RRMS patients with breakthrough disease activity after the initial two-course regimen, research suggests. While the drug was first approved to be given as two annual courses, a study involving 811 patients with RRMS found that giving additional third and possibly ...

Already a member?

Login to keep reading.

© 2021 the limbic